A Post-Approval Study of the LINX® Reflux Management System

NCT ID: NCT01940185

Last Updated: 2024-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Post-Approval Study of the LINX® Reflux Management System in a prospective, multicenter, single-arm study, with patients as their own control to monitor the safety and efficacy of the LINX implant procedure and device in a post-approval environment to supplement existing safety and efficacy data.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastroesophageal Reflux Disease (GERD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LINX device

Patients implanted with the LINX® Reflux Management System.

LINX device

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LINX device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is a candidate for treatment with the LINX Reflux Management System
* Patient has provided written informed consent for participation in the post-approval study.
* Patient has indicated a willingness to comply with study requirements and the follow-up schedule and assessments.
* Patient has been diagnosed with GERD as defined by abnormal pH testing.
* Patient continues to have chronic GERD symptoms despite maximum medical therapy for the treatment of reflux.

Exclusion Criteria

* Patients with suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials.
* Known circumstances that would make it unlikely for the patient to complete follow-up through 60 months.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Torax Medical Incorporated

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Keck Medical Center of Univeristy of Southern California

Los Angeles, California, United States

Site Status

University of California San Diego

San Diego, California, United States

Site Status

Swedish Medical Center/SurgOne

Englewood, Colorado, United States

Site Status

Albany Surgical

Albany, Georgia, United States

Site Status

Esophageal Institute of Atlanta, PC.

Atlanta, Georgia, United States

Site Status

Candler Hospital

Savannah, Georgia, United States

Site Status

Bingham Memorial Hospital

Blackfoot, Idaho, United States

Site Status

Beth Israel

Boston, Massachusetts, United States

Site Status

Cuyuna Regional Medical Center

Crosby, Minnesota, United States

Site Status

VIP Surg PLLC

Las Vegas, Nevada, United States

Site Status

University Hospitals Cleveland Medical Center - Geauga

Cleveland, Ohio, United States

Site Status

Ohio State University Wexner Medical Center

Columbus, Ohio, United States

Site Status

Knox Community Hospital

Mount Vernon, Ohio, United States

Site Status

The Oregon Clinic

Portland, Oregon, United States

Site Status

Allegheny Western Pennsylvania Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Virginia Hospital Center

Arlington, Virginia, United States

Site Status

Swedish Medical Center

Seattle, Washington, United States

Site Status

Gundersen Lutheran Medical Center

La Crosse, Wisconsin, United States

Site Status

Froedtert and Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Louie BE, Smith CD, Smith CC, Bell RCW, Gillian GK, Mandel JS, Perry KA, Birkenhagen WK, Taiganides PA, Dunst CM, McCollister HM, Lipham JC, Khaitan LK, Tsuda ST, Jobe BA, Kothari SN, Gould JC. Objective Evidence of Reflux Control After Magnetic Sphincter Augmentation: One Year Results From a Post Approval Study. Ann Surg. 2019 Aug;270(2):302-308. doi: 10.1097/SLA.0000000000002789.

Reference Type RESULT
PMID: 29697454 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

3545

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.